Analytical Data
-
Gene name
CDH18
- Application
-
Alternative Names
CDH14; EY-Cadherin
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13634
-
Expression Region
Gly54~Phe268
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDH18, or Cadherin 18, is a member of the cadherin superfamily, which is essential for cell adhesion and is vital in processes such as tissue development and maintenance. The study of CDH18 recombinant protein has gained significant attention due to its potential role in neurodevelopmental processes and various neuropsychiatric disorders. Research indicates that CDH18 is prominently expressed in the central nervous system, particularly in regions associated with cognitive functions and synaptic plasticity. Its involvement in the formation and stabilization of synapses suggests that disruptions in its expression or function could be linked to conditions like autism spectrum disorders and schizophrenia. Moreover, understanding the structural and functional properties of CDH18 through recombinant protein studies can provide insights into its mechanistic roles in cell-cell interactions and signaling pathways. This research is pivotal to unraveling the complexities of neurological diseases and could lead to the development of targeted therapies aimed at restoring normal cadherin function. Furthermore, CDH18's unique expression pattern and interaction with other signaling molecules position it as a potential biomarker for neurodevelopmental research. Hence, the exploration of CDH18 recombinant protein not only enhances our understanding of fundamental biological processes but also opens avenues for innovative therapeutic strategies in treating neurodevelopmental disorders.
